Section Arrow
AMGN.NASDAQ
- Amgen
Quotes are at least 15-min delayed:2026/04/25 11:25 EDT
Regular Hours
Last
 344.55
-4.07 (-1.17%)
Day High 
347.66 
Prev. Close
348.62 
1-M High
359.445 
Volume 
2.20M 
Bid
344.6
Ask
345
Day Low
342.52 
Open
346 
1-M Low
335.06 
Market Cap 
187.93B 
Currency 美元 
P/E 24.31 
%Yield 2.8 
10-SMA 349.43 
20-SMA 349.31 
50-SMA 361.55 
52-W High 391.29 
52-W Low 261.43 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
14.23/23.22
Enterprise Value
237.93B
Balance Sheet
Book Value Per Share
16.06
Cash Flow
Cash Flow Yield
0.05
Income Statement
Total Revenue
381.20M
Operating Revenue Per Share
49.78
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PFEPfizer27+0.33+1.24%19.61PE
OGNOrganon & Co11.26+2.66+30.93%11.87PE
NVONovo-Nordisk A/S41.17+2.65+6.88%10.72PE
ABBVABBVIE198.71-2.24-1.11%84.84PE
MRKMerck & Co111.9-2.72-2.37%15.67PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introducedits first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgenalso has a growing biosimilar portfolio.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.